Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB1518 for Myelodysplastic Syndrome (MDS)
NCT01436084Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2011
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pacritinib in myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Started Dec 2011; status: terminated.
02
Drugs
pacritinib
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01436084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01436084.